BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) has announced two significant shareholder returns initiatives. The company declared a quarterly dividend of $0.08 per share, payable on May 30, 2025, to shareholders of record as of May 19, 2025. Additionally, the Board approved a new $500 million share repurchase program effective May 8, 2025, replacing the previous program.

The timing and volume of share repurchases will be determined by various factors including share price, market conditions, and regulatory requirements. Bio-Techne, a global life sciences company providing research and clinical diagnostic tools, reported $1.2 billion in net sales for fiscal 2024 and employs approximately 3,100 people worldwide.

Positive

• New $500 million share repurchase program authorized
• Continued quarterly dividend payment of $0.08 per share
• Strong financial position with $1.2 billion in net sales for fiscal 2024

Negative

• Share repurchase program can be suspended or discontinued at any time
• Dividend amount remains unchanged, showing no growth

Insights

Financial Analyst

Bio-Techne announced a $0.08 quarterly dividend and substantial $500 million share repurchase program, representing significant capital return commitment relative to $1.2B annual revenue.

Bio-Techne's announcement features two key capital allocation decisions that warrant investor attention. First, the company declared a $0.08 per share quarterly dividend, payable May 30, 2025, to shareholders of record on May 19, 2025. The Board will continue evaluating dividends quarterly.

More substantially, the company authorized a new share repurchase program of up to $500 million, replacing its previous program. This authorization represents over 40% of the company's annual revenue, which the release states was approximately $1.2 billion in fiscal 2024.

The size of this buyback authorization is particularly notable relative to Bio-Techne's revenue base. Companies typically implement share repurchase programs when they generate excess cash beyond operational needs and see value in reducing outstanding shares. The program's flexible implementation allows management to adjust timing and volume based on market conditions and business needs.

This capital return strategy provides context for Bio-Techne's overall financial position as a global life sciences company with approximately 3,100 employees. The formal authorization of both ongoing dividends and the substantial share repurchase program suggests management confidence in the company's ability to generate sufficient cash flow to fund both shareholder returns and operational requirements.

MINNEAPOLIS, May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025. The quarterly dividend will be payable May 30, 2025, to all common shareholders of record on May 19, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Bio-Techne also announced this week that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $500 million of common stock. The new share repurchase program begins May 8, 2025 and replaces the previous program. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The share repurchase program may be suspended, amended, or discontinued at any time and does not obligate the Company to acquire any specific dollar amount or number of shares of common stock.

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio­-techne.com.

Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. Forward looking statements in this press release include statements regarding potential future repurchase of Bio-Techne common stock. The following important factors, among others, have affected and, in the future, could affect the Company's actual results and future share price: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact:	David Clair, Vice President, Investor Relations & Corporate Development
	David.Clair@bio-techne.com
	612-656-4416

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-declares-dividend-and-new-share-repurchase-program-302447833.html

SOURCE Bio-Techne Corporation

FAQ

What is the amount of Bio-Techne's (TECH) new share repurchase program in 2025?

Bio-Techne's Board approved a new $500 million share repurchase program effective May 8, 2025.

When will Bio-Techne (TECH) pay its quarterly dividend in 2025?

Bio-Techne will pay its $0.08 per share quarterly dividend on May 30, 2025, to shareholders of record as of May 19, 2025.

What was Bio-Techne's (TECH) net sales for fiscal 2024?

Bio-Techne generated approximately $1.2 billion in net sales during fiscal 2024.

How many employees does Bio-Techne (TECH) have globally?

Bio-Techne has approximately 3,100 employees worldwide.

What is Bio-Techne's (TECH) dividend per share for Q1 2025?

Bio-Techne's quarterly dividend is $0.08 per share for the quarter ended March 31, 2025.